Manuscripts and Publications

Filters: Author is Han, Meilan K  [Clear All Filters]
2023
Sowho MO, Koch AL, Putcha N, Woo H, Gassett A, Paulin LM, Koehler K, R Barr G, Comellas AP, Cooper CB et al..  2023.  Ambient Air Pollution Exposure and Sleep Quality in COPD.. Chronic Obstr Pulm Dis. 10(1):102-111.
Fortis S, Quibrera PM, Comellas AP, Bhatt SP, Tashkin DP, Hoffman EA, Criner GJ, Han MK, R Barr G, Arjomandi M et al..  2023.  Bronchodilator Responsiveness in Tobacco-Exposed People With or Without COPD.. Chest. 163(3):502-514.
W LeMaster B, P Quibrera M, Couper D, Tashkin DP, Bleecker ER, Doerschuk CM, Ortega VE, Cooper C, Han MK, Woodruff PG et al..  2023.  Clinical Implications of Low Absolute Blood Eosinophil Count in the SPIROMICS COPD Cohort.. Chest. 163(3):515-528.
Barjaktarevic I, Cooper CB, Shing T, Buhr RG, Hoffman EA, Woodruff PG, M Drummond B, Kanner RE, Han MK, Hansel NN et al..  2023.  Impact of Marijuana Smoking on COPD Progression in a Cohort of Middle-Aged and Older Persons. Chronic Obstr Pulm Dis.
Wang JM, Labaki WW, Murray S, Martinez FJ, Curtis JL, Hoffman EA, Ram S, Bell AJ, Galbán CJ, Han MK et al..  2023.  Machine learning for screening of at-risk, mild and moderate COPD patients at risk of FEV1 decline: results from COPDGene and SPIROMICS. Front Physiol. 14:1144192.
Chaudhary MFA, Hoffman EA, Guo J, Comellas AP, Newell JD, Nagpal P, Fortis S, Christensen GE, Gerard SE, Pan Y et al..  2023.  Predicting severe chronic obstructive pulmonary disease exacerbations using quantitative CT: a retrospective model development and external validation study.. Lancet Digit Health. 5(2):e83-e92.
Angelini ED, Yang J, Balte PP, Hoffman EA, Manichaikul AW, Sun Y, Shen W, Austin JHM, Allen NB, Bleecker ER et al..  2023.  Pulmonary emphysema subtypes defined by unsupervised machine learning on CT scans. Thorax.
LaFon DC, Woo H, Fedarko N, Azar A, Hill H, Tebo AE, Martins TB, Han MK, Krishnan JA, Ortega VE et al..  2023.  Reduced quantity and function of pneumococcal antibodies are associated with exacerbations of COPD in SPIROMICS.. Clin Immunol. 250:109324.
2022
Krishnan JK, Ancy KM, Oromendia C, Hoffman KL, Easthausen I, Leidy NK, Han MK, Bowler RP, Christenson SA, Couper DJ et al..  2022.  Characterizing COPD Symptom Variability in the Stable State Utilizing the Evaluating Respiratory Symptoms in COPD Instrument.. Chronic Obstr Pulm Dis. 9(2):195-208.
Barjaktarevic I, Cooper CB, Shing T, Buhr RG, Hoffman EA, Woodruff PG, M Drummond B, Kanner RE, Han MK, Hansel NN et al..  2022.  Effect of marijuana smoking on lung function change in older ever tobacco smokers.. Eur Respir J. 60(3)
Ronish BE, Couper DJ, Barjaktarevic IZ, Cooper CB, Kanner RE, Pirozzi CS, Kim V, Wells JM, Han MK, Woodruff PG et al..  2022.  Forced Expiratory Flow at 25%-75% Links COPD Physiology to Emphysema and Disease Severity in the SPIROMICS Cohort.. Chronic Obstr Pulm Dis. 9(2):111-121.
Esther CR, O'Neal WK, Anderson WH, Kesimer M, Ceppe A, Doerschuk CM, Alexis NE, Hastie AT, R Barr G, Bowler RP et al..  2022.  Identification of Sputum Biomarkers Predictive of Pulmonary Exacerbations in COPD.. Chest. 161(5):1239-1249.
Madapoosi SS, Cruickshank-Quinn C, Opron K, Erb-Downward JR, Begley LA, Li G, Barjaktarevic I, R Barr G, Comellas AP, Couper DJ et al..  2022.  Lung Microbiota and Metabolites Collectively Associate with Clinical Outcomes in Milder Stage Chronic Obstructive Pulmonary Disease.. Am J Respir Crit Care Med. 206(4):427-439.
Baugh AD, Shiboski S, Hansel NN, Ortega V, Barjaktarevic I, R Barr G, Bowler R, Comellas AP, Cooper CB, Couper D et al..  2022.  Reconsidering the Utility of Race-Specific Lung Function Prediction Equations.. Am J Respir Crit Care Med. 205(7):819-829.
Buhr RG, Barjaktarevic IZ, P Quibrera M, Bateman LA, Bleecker ER, Couper DJ, Curtis JL, Dolezal BA, Han MK, Hansel NN et al..  2022.  Reversible Airflow Obstruction Predicts Future Chronic Obstructive Pulmonary Disease Development in the SPIROMICS Cohort: An Observational Cohort Study.. Am J Respir Crit Care Med. 206(5):554-562.
Yee N, Markovic D, Buhr RG, Fortis S, Arjomandi M, Couper D, Anderson WH, Paine R, Woodruff PG, Han MK et al..  2022.  Significance of FEV/FEV in Recognition of Early Airway Disease in Smokers at Risk of Development of COPD: Analysis of the SPIROMICS Cohort.. Chest. 161(4):949-959.
2021
Burkes RM, Couper DJ, Barjaktarevic IZ, Cooper CB, Labaki WW, Han MK, Woodruff PG, Lazarus SC, Parekh TM, Paine R et al..  2021.  Age-Dependent Associations Between 25-Hydroxy Vitamin D Levels and COPD Symptoms: Analysis of SPIROMICS.. Chronic Obstr Pulm Dis. 8(2):277-291.
Radicioni G, Ceppe A, Ford AA, Alexis NE, R Barr G, Bleecker ER, Christenson SA, Cooper CB, Han MK, Hansel NN et al..  2021.  Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.. Lancet Respir Med. 9(11):1241-1254.
Zhang WZ, Hoffman KL, Schiffer KT, Oromendia C, Rice MC, Barjaktarevic I, Peters SP, Putcha N, Bowler RP, J Wells M et al..  2021.  Association of plasma mitochondrial DNA with COPD severity and progression in the SPIROMICS cohort.. Respir Res. 22(1):126.
Ejike CO, Woo H, Galiatsatos P, Paulin LM, Krishnan JA, Cooper CB, Couper DJ, Kanner RE, Bowler RP, Hoffman EA et al..  2021.  Contribution of Individual and Neighborhood Factors to Racial Disparities in Respiratory Outcomes.. Am J Respir Crit Care Med. 203(8):987-997.
Oh AL, Mularski RA, Barjaktarevic I, R Barr G, Bowler RP, Comellas AP, Cooper CB, Criner GJ, Han MK, Hansel NN et al..  2021.  Defining Resilience to Smoking-related Lung Disease: A Modified Delphi Approach from SPIROMICS.. Ann Am Thorac Soc. 18(11):1822-1831.
Kasela S, Ortega VE, Martorella M, Garudadri S, Nguyen J, Ampleford E, Pasanen A, Nerella S, Buschur KL, Barjaktarevic IZ et al..  2021.  Genetic and non-genetic factors affecting the expression of COVID-19-relevant genes in the large airway epithelium.. Genome Med. 13(1):66.
Turnier L, Eakin M, Woo H, Dransfield M, Parekh T, Krishnan JA, Kanner R, Cooper CB, Woodruff PG, Wise R et al..  2021.  The influence of social support on COPD outcomes mediated by depression.. PLoS One. 16(3):e0245478.
Opron K, Begley LA, Erb-Downward JR, Freeman C, Madapoosi S, Alexis NE, Barjaktarevic I, R Barr G, Bleecker ER, Bowler RP et al..  2021.  Lung microbiota associations with clinical features of COPD in the SPIROMICS cohort.. NPJ Biofilms Microbiomes. 7(1):14.
Zusman M, Gassett AJ, Kirwa K, R Barr G, Cooper CB, Han MK, Kanner RE, Koehler K, Ortega VE, Rd RPaine et al..  2021.  Modeling residential indoor concentrations of PM , NO , NO , and secondhand smoke in the Subpopulations and Intermediate Outcome Measures in COPD (SPIROMICS) Air study.. Indoor Air. 31(3):702-716.

Pages